The Women’s Health Gap: Why So Many Conditions Still Go Undiagnosed
For decades, women’s symptoms were too often misunderstood, their biology under-researched, and their pain dismissed. Science is making progress—but important gaps remain.
From endometriosis and menstrual health to medication safety and pain management, women’s healthcare is shaped by a long history of scientific blind spots. Understanding how those gaps developed is an important step toward better diagnosis, more effective treatments and a healthcare system that listens.
When Women’s Pain Is Treated as Normal
For many women, seeking medical help for severe period pain, persistent pelvic discomfort or unexplained symptoms can become a frustrating journey. Some receive effective treatment quickly. Others spend years searching for answers, hearing that their symptoms are normal or that hormonal contraception is the only option worth considering.
Hormonal treatments can be valuable for several reproductive conditions. The problem arises when treatment becomes a substitute for investigating persistent symptoms or discussing alternatives.
This is part of a broader challenge in women’s health: medical knowledge has expanded considerably, but some conditions remain difficult to diagnose, and research has not answered every question about female biology.
The gap did not appear overnight. It developed through decades of research priorities, regulatory decisions and assumptions about whose bodies could serve as the standard for medical science.
How Medical Research Left Women Behind
Historically, women were underrepresented in many clinical studies. Researchers sometimes excluded women who could become pregnant because of concerns about potential harm to a fetus. Hormonal fluctuations were also treated as a complicating factor in research design.
These decisions were often presented as ways to simplify studies or protect participants. Yet exclusion created its own risks: evidence gathered predominantly from men could not always explain how diseases, medications or treatments affect women.
A major turning point came with the US National Institutes of Health Revitalization Act of 1993. It required the NIH to establish policies ensuring that women and racial and ethnic minority groups were included in NIH-supported clinical research, helping move medical science toward more representative studies. NIH source
Inclusion, however, is only the beginning. Researchers must also analyse results by sex and other relevant factors, investigate differences in treatment response and ensure that findings translate into appropriate clinical care.
Three Historical Warnings That Changed Drug Safety
Several medical events helped shape modern attitudes toward pharmaceutical safety.
Thalidomide exposed the danger of inadequate evidence. In the late 1950s and early 1960s, thalidomide was used in several countries, including for pregnancy-related nausea. Exposure during pregnancy caused severe birth defects. In the United States, FDA reviewer Frances Oldham Kelsey refused to approve the drug because the safety evidence was inadequate. Her decision helped prevent a comparable national tragedy. FDA history
Diethylstilbestrol, or DES, revealed risks that emerged decades later. This synthetic estrogen was prescribed to pregnant women in the belief that it could prevent complications. Later research linked prenatal exposure to rare reproductive tract cancers and other reproductive problems in some offspring. The case demonstrated why medicines must be evaluated for long-term effects, not merely immediate outcomes.
The Dalkon Shield IUD raised serious concerns about device safety. Introduced in the early 1970s, this contraceptive device was associated with pelvic infections and severe complications. Its multifilament string design was implicated in the movement of bacteria, and the controversy damaged public confidence in contraceptive care.
These events reinforced the need for rigorous testing and informed consent. But protecting patients should not mean excluding them from research indefinitely. The goal must be to study treatments carefully in the populations who may need them.
Endometriosis Shows Why the Gap Matters Today
Endometriosis affects approximately one in ten women of reproductive age worldwide, according to the World Health Organization. It occurs when tissue similar to the lining of the uterus grows outside it, potentially causing severe pain, inflammation and fertility problems.
Diagnosis can be challenging because symptoms vary and overlap with other conditions. A 2026 systematic review examined whether menstrual blood could provide biomarkers to help identify endometriosis without invasive procedures. The researchers found promising candidates, but concluded that much of the evidence remains exploratory and requires further validation. Research review
This is an encouraging direction, not yet a replacement for established clinical assessment. Still, it illustrates what becomes possible when researchers investigate biological material that was historically overlooked.
Pain, Consent and Better Conversations
Research gaps also influence everyday healthcare experiences. Procedures such as intrauterine device (IUD) insertion and cervical biopsies can cause discomfort or pain, yet patients have not always received sufficient information about pain-management options.
Care should involve explaining what a procedure may feel like, discussing available pain relief, respecting consent and responding seriously when a patient reports discomfort.
The same principle applies to persistent menstrual pain, unusual bleeding or symptoms that interfere with daily life. These concerns deserve assessment rather than automatic dismissal.
What Better Women’s Healthcare Should Look Like
Closing the gap requires more than funding a few additional studies. It means including diverse participants in research, examining sex-specific differences, improving diagnostic tools and making sure clinical guidelines reflect the best available evidence.
It also means listening to patients. Women should feel able to describe their symptoms, ask why a treatment is recommended and discuss reasonable alternatives. Clinicians, in turn, need time and resources to investigate complex problems rather than relying on a one-size-fits-all response.
Progress is happening, but scientific discovery does not automatically guarantee better care. New tests need validation, treatments need rigorous trials, and research findings must reach the people who need them.
Women’s health is not a niche branch of medicine. It is central to public health. The lesson from decades of missed opportunities is straightforward: when research overlooks a population, the consequences can follow patients into the consulting room.
Better healthcare begins when women’s experiences are treated not as exceptions to the medical story, but as essential evidence for understanding it.
Photo by Becca Tapert on Unsplash